Search Results

You are looking at 81 - 90 of 135 items for :

Clear All
Full access

response, modification of therapy, and candidacy for early alloHSCT. Dr. Park noted that both gene sequencing tests are validated, so patient preference should take priority. Incorporation of tyrosine kinase inhibitors (TKIs) in Ph-like ALL is being

Full access

with ovarian cancer into clinical trials must be encouraged. Second-Line TKIs Offer Expanded Treatment Options for Newly Diagnosed Patients with CML Second-generation tyrosine kinase inhibitor (TKI) therapies approved for first-line therapy of

Full access

Toni K. Choueiri and Robert J. Motzer

inhibitor (TKI) against VEGFR and MET, in a highly pretreated RCC population. 8 Cabozantinib is being compared with standard everolimus in a randomized phase III trial (METEOR) in patients with VEGFR-TKI–refractory RCC ( ClinicalTrials.gov identifier: NCT

Full access

Gregory J. Riely, Jamie E. Chaft, Marc Ladanyi and Mark G. Kris

inhibitors (TKIs). Both drugs were initially identified, developed, and eventually FDA-approved for treatment of all people with advanced non-small cell lung cancers (NSCLCs). Since 2004, however, it has become clear that the benefits of erlotinib and

Full access

Joseph C. Alvarnas, Patrick A. Brown, Patricia Aoun, Karen Kuhn Ballen, Naresh Bellam, William Blum, Michael W. Boyer, Hetty E. Carraway, Peter F. Coccia, Steven E. Coutre, Jennifer Cultrera, Lloyd E. Damon, Daniel J. DeAngelo, Dan Douer, Haydar Frangoul, Olga Frankfurt, Salil Goorha, Michael M. Millenson, Susan O'Brien, Stephen H. Petersdorf, Arati V. Rao, Stephanie Terezakis, Geoffrey Uy, Meir Wetzler, Andrew D. Zelenetz, Maoko Naganuma and Kristina M. Gregory

improvements in outcomes in some subtypes of ALL. These agents include BCR-ABL selective tyrosine kinase inhibitors (TKIs) for Ph-positive ALL, 51 – 58 and anti-CD20 monoclonal antibody (e.g., rituximab) for CD20-expressing B-cell lineage ALL (especially for

Full access

607 610 610 jnccn195009 10.6004/jnccn.2019.5009 NCCN Guidelines Updates: Discontinuing TKI Therapy in the Treatment of Chronic Myeloid Leukemia Shah Neil P. MD, PhD 05 2019 17 17 5.5 5.5 611 611 613 613 jnccn195013 10.6004/jnccn.2019.5013 Mutation

Full access

Response to TKI Therapy in Chronic Myelogenous Leukemia Therapeutic Advances in the Treatment of CLL: Focus on Inhibitors of the BCR Signaling Pathways Skin Malignancies Melanoma Guideline Update: New Agents and Opportunities for Treatment

Full access

Use in Patients with Cancer; Optimizing Oral Therapy in Kidney Cancer Management of Cardiovascular Toxicities Associated with TKI Therapy Management of Hypersensitivity Reactions to Systemic Therapy Safe Handling of Hazardous Drugs Implementing

Full access

Amit Mahipal, Minsig Choi and Richard Kim

Agents: Apatinib is an oral tyrosine kinase inhibitor (TKI) of VEGFR-2 that has demonstrated activity in gastric cancer. Results were recently reported of the placebo-controlled phase III trial conducted in China involving 270 patients. 7 Patients must

Full access

Sara E. Nunnery, Andrew E. Fintel, W. Clay Jackson, Jason C. Chandler, Michael O. Ugwueke and Mike G. Martin

States. CML can be well controlled with systemic treatment, but the cost can be daunting. 10 Oral tyrosine kinase inhibitors (TKIs) such as imatinib can control the disease long-term and are the initial treatment of choice. However, in the United